LONDON--(BUSINESS WIRE)--Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in its Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK). This brings total Series-A funding to £14.5 million from our syndicate of investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France).
